Cargando…

Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma

PURPOSE: Large cell neuroendocrine carcinoma (LCNEC) and classic large cell carcinoma (LCC) are two distinct entities with different histological and biological characteristics. However, the mutational profiles and the clinical behavior of the two subtypes of lung cancer remain to be explored. PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ying, Cui, Xiaoying, Wang, Di, Xia, Guojie, Xing, Minyan, Cheng, Lei, Sheng, Liming, Du, Xianghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796852/
https://www.ncbi.nlm.nih.gov/pubmed/35096557
http://dx.doi.org/10.3389/fonc.2021.664397
_version_ 1784641410223308800
author Chen, Ying
Cui, Xiaoying
Wang, Di
Xia, Guojie
Xing, Minyan
Cheng, Lei
Sheng, Liming
Du, Xianghui
author_facet Chen, Ying
Cui, Xiaoying
Wang, Di
Xia, Guojie
Xing, Minyan
Cheng, Lei
Sheng, Liming
Du, Xianghui
author_sort Chen, Ying
collection PubMed
description PURPOSE: Large cell neuroendocrine carcinoma (LCNEC) and classic large cell carcinoma (LCC) are two distinct entities with different histological and biological characteristics. However, the mutational profiles and the clinical behavior of the two subtypes of lung cancer remain to be explored. PATIENTS AND METHODS: Pathological diagnoses of all screened patients were finally confirmed by three or four experienced pathologists. Patients with uncertain pathological diagnoses were excluded. Finally, we genetically profiled ten patients with LCNEC and seven with LCC. ALL patients were subjected to next-generation sequencing (NGS) test, which included nine patients sequenced with a 139-gene panel and eight patients with a 425-gene panel. Including only intersected mutations from these two panels, survival analysis was further conducted. RESULTS: Both LCNEC and LCC showed high prevalence in male patients, with no clear association with smoking history. Potential targetable mutations in KRAS and RET were detected in the study cohort. However, LCNEC and LCC showed distinct mutational profiles with an enrichment of RB1/TP53 co-mutations in a subset of LCNEC patients. SMARCA4 and KEAP1 mutations were exclusively found in LCC patients, and RICTOR, BRAF, ROS1 and TET2 mutations were only detected in LCNEC. LCC patients in the cohort had shorter survival compared to LCNEC patients (p=0.006). Survival analysis revealed an association between SMARCA4 mutations and poor outcome in the study cohort and in the LCC subset. Mutations in BRAF were associated with a trend of increased survival in the study cohort, as well as in the LCNEC subset. Finally, TET2 mutations were associated with poor outcome in the LCNEC cohort. CONCLUSION: LCC and LCNEC were both heterogeneous diseases with limited treatment options. Our study identified potential targetable mutations and prognostic biomarkers that might provide more therapeutic options and improve individualized patient care.
format Online
Article
Text
id pubmed-8796852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87968522022-01-29 Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma Chen, Ying Cui, Xiaoying Wang, Di Xia, Guojie Xing, Minyan Cheng, Lei Sheng, Liming Du, Xianghui Front Oncol Oncology PURPOSE: Large cell neuroendocrine carcinoma (LCNEC) and classic large cell carcinoma (LCC) are two distinct entities with different histological and biological characteristics. However, the mutational profiles and the clinical behavior of the two subtypes of lung cancer remain to be explored. PATIENTS AND METHODS: Pathological diagnoses of all screened patients were finally confirmed by three or four experienced pathologists. Patients with uncertain pathological diagnoses were excluded. Finally, we genetically profiled ten patients with LCNEC and seven with LCC. ALL patients were subjected to next-generation sequencing (NGS) test, which included nine patients sequenced with a 139-gene panel and eight patients with a 425-gene panel. Including only intersected mutations from these two panels, survival analysis was further conducted. RESULTS: Both LCNEC and LCC showed high prevalence in male patients, with no clear association with smoking history. Potential targetable mutations in KRAS and RET were detected in the study cohort. However, LCNEC and LCC showed distinct mutational profiles with an enrichment of RB1/TP53 co-mutations in a subset of LCNEC patients. SMARCA4 and KEAP1 mutations were exclusively found in LCC patients, and RICTOR, BRAF, ROS1 and TET2 mutations were only detected in LCNEC. LCC patients in the cohort had shorter survival compared to LCNEC patients (p=0.006). Survival analysis revealed an association between SMARCA4 mutations and poor outcome in the study cohort and in the LCC subset. Mutations in BRAF were associated with a trend of increased survival in the study cohort, as well as in the LCNEC subset. Finally, TET2 mutations were associated with poor outcome in the LCNEC cohort. CONCLUSION: LCC and LCNEC were both heterogeneous diseases with limited treatment options. Our study identified potential targetable mutations and prognostic biomarkers that might provide more therapeutic options and improve individualized patient care. Frontiers Media S.A. 2022-01-14 /pmc/articles/PMC8796852/ /pubmed/35096557 http://dx.doi.org/10.3389/fonc.2021.664397 Text en Copyright © 2022 Chen, Cui, Wang, Xia, Xing, Cheng, Sheng and Du https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Ying
Cui, Xiaoying
Wang, Di
Xia, Guojie
Xing, Minyan
Cheng, Lei
Sheng, Liming
Du, Xianghui
Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
title Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
title_full Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
title_fullStr Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
title_full_unstemmed Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
title_short Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
title_sort molecular characterization and prognostication of large cell neuroendocrine carcinoma and large cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796852/
https://www.ncbi.nlm.nih.gov/pubmed/35096557
http://dx.doi.org/10.3389/fonc.2021.664397
work_keys_str_mv AT chenying molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT cuixiaoying molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT wangdi molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT xiaguojie molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT xingminyan molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT chenglei molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT shengliming molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma
AT duxianghui molecularcharacterizationandprognosticationoflargecellneuroendocrinecarcinomaandlargecellcarcinoma